Roivant Sciences/$ROIV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Ticker
$ROIV
Sector
Primary listing
Employees
721
Headquarters
Website
Roivant Sciences Metrics
BasicAdvanced
$21bn
-
-$0.54
1.14
-
Price and volume
Market cap
$21bn
Beta
1.14
52-week high
$32.79
52-week low
$10.71
Average daily volume
6m
Financial strength
Current ratio
18.373
Quick ratio
17.999
Long term debt to equity
1.819
Total debt to equity
2.03
Profitability
EBITDA (TTM)
-1,276.555
Gross margin (TTM)
-8,169.94%
Net profit margin (TTM)
-3,629.19%
Operating margin (TTM)
-15,495.19%
Effective tax rate (TTM)
-50.39%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-14.22%
Return on equity (TTM)
-7.59%
Valuation
Price to revenue (TTM)
2,400.874
Price to book
4.55
Price to tangible book (TTM)
4.55
Price to free cash flow (TTM)
-26.143
Free cash flow yield (TTM)
-3.83%
Free cash flow per share (TTM)
-1.093
Growth
Revenue change (TTM)
-71.57%
Earnings per share change (TTM)
128.72%
3-year revenue growth (CAGR)
-36.01%
3-year earnings per share growth (CAGR)
-27.51%
What the Analysts think about Roivant Sciences
Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.
Roivant Sciences Financial Performance
Revenues and expenses
Roivant Sciences Earnings Performance
Company profitability
Roivant Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs